Skip to content
value.today
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

Total raised
$27 M
1 round on record
Latest round
$27 M
Jun 2021
First round on record
Jun 2021
Today
Went public
See the company page

BriaCell Therapeutics Corp. is listed today as Briacell Therapeutics Corp.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of BriaCell Therapeutics Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$27 MNo. 1$10 to $50 million

BriaCell Therapeutics Corp.: Raise no. 1, Jun 2021

Investors in this round

12 investors had bought by the notice of Jun 15, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,175,680
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Gadi Levin · Executive Officer
  • Jamieson Bondarenko · Executive Officer, Director
  • William Williams · Executive Officer, Director
  • Martin Schmieg · Director
  • Rebecca Taub · Director
  • Vaughn Embro-Pantalony · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ThinkEquity, a division of Fordham Financial Management, Inc. (CRD 20996) · New York, New YorkSold in CA, NJ, NV, NY

Remarks in the notice

  • On fees: “The above amount reflects a cash fee equal to 8% of gross proceeds, including exercise price of the pre-funded warrants. The Placement Agent also received a number of warrants equal to 5% of the Units sold in this offering.”
  • On the amounts: “Offering consists of 4,370,343 common shares at a purchase price of USD 5.26; 800,000 pre-funded warrants at a purchase price of USD 5.25 with an exercise price of USD 0.01 per share and 5,170,343 warrants with an exercise price of USD 6.19 per share”

Signed by William V. Williams, Chief Executive Officer. Newest notice filed Jun 15, 2021. Read the notice at the SEC.

equity, optionsSEC
Nov 2014$6 MIssued in a merger or acquisition$2 to $10 million

BriaCell Therapeutics Corp.: Private sale, Nov 2014

Investors in this round

7 investors had bought by the notice of Dec 12, 2014: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: 833,333 Warrants are exercisable to purchase one additional common share at price of $0.25 for first 12 months after closing and $0.35 during the subsequent 24 months.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
not stated
Sales commissions
none
Finders' fees
$1
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Charles Wiseman · Executive Officer, Director
  • Rahoul A. Sharan · Executive Officer, Director
  • Isaac A. Maresky · Director
  • Saeid Babei · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “1 PowerOne Capital Markets Limited of Toronto, Ontario, received 200,000 shares as a finder's fee for introducing the Issuer to BriaCell Therapeutics Corp.”
  • On the amounts: “Represents value of common shares issued in connection with share exchange, valued at Cdn$0.18 per share; Cdn$1.1333=US$1.00”
  • On a merger: “Acquisition of BriaCell Therapeutics Corp. by Ansell Capital Corp.”

Signed by Matthew G. Wright, Chief Financial Officer. Newest notice filed Dec 12, 2014. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BriaCell Therapeutics Corp. chose not to state its revenue in its newest notice of a funding round (Jun 2021).

    SEC Form D · Jun 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2021

Products and services#

No products or services of BriaCell Therapeutics Corp. are on record.

Investors#

No investor of BriaCell Therapeutics Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Briacell Therapeutics Corp. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BriaCell Therapeutics Corp.
NameRoleNamed in
Gadi LevinExecutive officerJun 2021
Jamieson BondarenkoExecutive officerJun 2021
William WilliamsExecutive officerJun 2021
Charles WisemanExecutive officerDec 2014
Rahoul A. SharanExecutive officerDec 2014
Jamieson BondarenkoDirectorJun 2021
Martin SchmiegDirectorJun 2021
Rebecca TaubDirectorJun 2021
Vaughn Embro-PantalonyDirectorJun 2021
William WilliamsDirectorJun 2021
Charles WisemanDirectorDec 2014
Isaac A. MareskyDirectorDec 2014
Rahoul A. SharanDirectorDec 2014
Saeid BabeiDirectorDec 2014

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.